Eligible patients had pathologically confirmed advanced solid tumors, whose disease was refractory to prior therapies or for whom no further standard therapy existed. Patients were required to be ≥ 18 years of age; with Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ ...